改訂5版 必ず役立つ! 肝炎診療バイブル

出版社: メディカ出版
著者:
発行日: 2021-08-01
分野: 臨床医学:内科  >  肝/胆/膵
ISBN: 9784840475679
電子書籍版: 2021-08-01 (電子書籍版)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

5,280 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

商品紹介

第8版・C型肝炎治療ガイドライン対応
肝炎診療の必携書籍「肝炎診療バイブル」の改訂5版がついに刊行。第8版・C型肝炎治療ガイドラインの最新情報、第3.4版・B型肝炎治療ガイドラインをいち早く収載し、各種ガイドラインに準拠した必須知識もさらにパワーアップ。消化器内科を目指す研修医・レジデント必携の一冊!

目次

  • <1 肝機能検査の読みかた>
    ■1 検査オーダーの流れ
    ■2 肝機能検査
    ■3 末梢血検査
    ■4 止血・凝固検査
    ■5 肝腫瘍マーカー
    ■6 肝線維化マーカー

    <2 画像検査のポイント>
    ■1 検査オーダーの流れ
    ■2 腹部超音波検査(腹部エコー)
    ■3 腹部CT検査
    ■4 腹部MRI検査
    ■5 血管造影検査

    <3 C型肝炎の診断と治療>
    ■1 C型肝炎をより理解するためのウイルス遺伝子とヒト遺伝子
    ■2 C型肝炎患者の自然史
    ■3 C型慢性肝炎の診断と評価
    ■4 C型肝炎治療薬DAA
    ■5 C型肝炎治療ガイドライン
    ■6 肝庇護療法など

    <4 B型肝炎の診断と治療>
    ■1 B型肝炎ウイルスの基礎知識
    ■2 B型慢性肝炎の自然史と診断
    ◆1 B型慢性肝疾患患者の自然経過
    ◆2 HBVの母子感染と予防対策
    ■3 B型慢性肝炎の治療
    ◆1 B型慢性肝炎の治療指針
    ◆2 インターフェロン治療
    ◆3 核酸アナログ
    ◆4 その他の治療

    <5 HIV重複感染患者の管理>
    ■1 HIV感染の基礎知識
    【補足】HIV感染者の消化管病変
    ■2 HIV感染者のB型肝炎
    ■3 HIV感染者のC型肝炎

    <6 自己免疫性肝疾患の診断と治療>
    ■1 自己免疫性肝炎(AIH)
    ■2 原発性胆汁性胆管炎(PBC)
    ■3 原発性硬化性胆管炎(PSC)

    <7 アルコール性肝障害の診断と治療>
    ■アルコール性肝障害の診断と治療

    <8 脂肪肝・脂肪肝炎の診断と治療>
    ■非アルコール性脂肪性肝疾患(NAFLD)と非アルコール性脂肪肝炎(NASH)の診断と治療

    <9 薬物性肝障害の診断と治療>
    ■薬物性肝障害の診断と治療

    <10 肝硬変の治療>
    ■1 肝硬変の成因と治療
    ■2 肝硬変の栄養管理(サルコペニアを含む)
    ■3 合併症の管理
    ◆1 肝性脳症の診断と治療
    ◆2 門脈圧亢進症:食道・胃静脈瘤、門脈圧亢進性胃症(PHG)

    <11 肝癌の診断と治療>
    ■1 肝癌の分類と肝腫瘍の組織分類
    ■2 肝癌の診断
    ■3 肝癌の治療
    ◆1 肝細胞癌に対する治療選択
    ◆2 肝切除
    ◆3 肝動脈塞栓療法(TACE/TAE)
    ◆4 局所治療
    ◆5 化学療法(分子標的治療)
    ◆6 緩和ケア

    <12 肝移植>
    ■1 肝移植の現状
    ■2 肝移植手術と管理

    <13 急性肝炎の診断と治療>
    ■1 急性肝炎の鑑別診断と治療
    ■2 劇症肝炎の診断と治療

    <14 肝病理組織の基礎知識>
    ■1 肝生検:その意義と基本組織構築
    ■2 ウイルス性肝炎と新犬山分類
    ■3 自己免疫性肝炎(AIH)と原発性胆汁性胆管炎(PBC)
    ■4 アルコール性肝障害と非アルコール性脂肪性肝疾患
    ■5 肝細胞癌と肝内胆管癌(胆管細胞癌)

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] 肝機能検査の読みかた

P.7 掲載の参考文献
1) 日本消化器病学会肝機能研究班. 肝機能検査法の選択基準 (7版). 日本消化器病学会雑誌. 103 (12), 2006, 1413-9.
2) 日本消化器病学会肝機能研究班. 肝疾患における肝炎ウイルスマーカーの選択基準 (4版). 日本消化器病学会雑誌. 103 (12), 2006, 1403-12.
3) Takahashi, A. et al. Autoimmune hepatitis in Japan : trends in a nationwide survey. J Gastroenterol. 52 (5), 2017, 631-40.
4) 熊田博光. "肝機能検査の読み方とチェックポイント「異常のときの考え方・対処法」". 肝疾患診療マニュアル. 日本医師会編. 東京, 診断と治療社, 1999, 38-40.
5) Miyakawa, Y. et al. Classifying hepatitis B virus genotypes. Intervirology. 46 (6), 2003, 329-38.
P.13 掲載の参考文献
1) 日本小児栄養消化器肝臓学会ほか. Wilson病診療ガイドライン 2015. 日本小児栄養消化器肝臓学会雑誌. 29 (2), 2015, 63-119.
2) 日本消化器病学会肝機能研究班. 肝機能検査法の選択基準 (7版). 日本消化器病学会雑誌. 103 (12), 2006, 1413-9.
P.15 掲載の参考文献
1) 堤久. 主に白血病・腫瘍性疾患以外の病態. 日本老年医学会雑誌. 51 (6), 2014, 517-25.
2) Helman, RA. et al. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med. 1971, 74 (3), 311-21.
3) 武内重五郎編. アルコール性肝障害-本邦における臨床とその特徴. 朝倉書店, 東京, 1988, 278-82.
7) 塩野義製薬. ムルプレタ錠 3mg. 適正使用ガイド. 2019年10月改訂.
P.17 掲載の参考文献
1) Liebman, HA. et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 310 (22), 1984, 1427-31.
2) Fujiyama, S. et al. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Hepatogastroenterology. 33 (5), 1986, 201-5.
3) Nakao, A. et al. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol. 86 (1), 1991, 62-6.
4) Sherlock, Sほか. シャーロック肝臓病学. 第II版. 小俣政男訳. 東京, 西村書店, 2004.
P.19 掲載の参考文献
1) 日本肝臓学会編. 肝癌診療ガイドライン2017年版補訂版. 東京, 金原出版, 2017, 25-42.
2) Bergstrand, CG. et al. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab lnvest. 8 (2), 1956, 174.
3) Taketa, K. et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenteology. 99 (2), 1990, 508-18.
4) 青柳豊ほか. AFP濃度, AFP L3分画, PIVKA-II. 肝・胆・膵. 60 (4), 2010, 669-79.
7) 日本肝臓学会編. 肝臓専門医テキスト. 改訂第3版. 東京, 南江堂, 2020, 106-9.
P.21 掲載の参考文献
1) 村脇義和ほか. 線維化マーカー. 肝胆膵. 60 (4), 2010, 559-67.
3) Kuno, A. et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 3, 2013, 1065-73.

[2] 画像検査のポイント

P.26 掲載の参考文献
1) 日本肝臓学会編. 肝癌診療ガイドライン2017年版補訂版. 東京, 金原出版, 2020.
P.35 掲載の参考文献
1) 日本肝癌研究会編. 臨床・病理 原発性肝癌取扱い規約. 第6版補訂版. 東京, 金原出版, 2019.
2) 二村雄次. 画像で知る肝区域. 消化器画像. 3, 2001, 429-31.
P.45 掲載の参考文献
1) 小塚隆弘ほか. 診療放射線技術 上巻. 改訂第14版. 東京, 南江堂, 2019, 279-81.
2) Pearce, MS. et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours : a retrospective cohort study. Lancet. 380 (9840), 2012, 499-505.
3) 日本医学放射線学会. "造影剤の安全性 : 造影剤腎症とNS". 画像診断ガイドライン. 2016年版. 東京, 金原出版, 2016, 37-41.
4) 日本医学放射線学会. "小児画像診断の考え方, 進め方". 画像診断ガイドライン. 2016年版. 東京, 金原出版, 2016, 51-3.
5) 日本医学放射線学会. "消化器領域の標準的撮像法". 画像診断ガイドライン. 2016年版. 東京, 金原出版, 2016, 260-7.
6) 日本産科婦人科学会・日本産婦人科医会編. 産婦人科診療ガイドライン-産科編 2017. 東京, 日本産科婦人科学会事務局, 2017, 67-71.
7) 坪山尚寛. 妊娠中のCT, MRIの安全性と産科救急. 画像診断. 39 (7), 2019, 675-84.
9) 日本腎臓学会・日本医学放射線学会・日本循環器学会編. 腎障害患者におけるヨード造影剤使用に関するガイドライン 2018. 東京, 東京医学社, 2018, 8-17.
10) 欧州泌尿生殖器放射線学会. ESUR造影剤ガイドライン version 10.0 (ハンドブック). 東京, シュプリンガージャパン, 2018, 21-8.
11) ビグアナイド薬の適正使用に関する委員会. メトホルミンの適正使用に関するRecommendation. 2020. https://www.nittokyo.or.jp/modules/information/index.php?content_id=23 (2021年5月20日閲覧)
12) Shinagawa, Y. et al. Usefulness of new subtraction algorithm in estimating degree of liver fibrosis by calculating extracellular volume fraction obtained from routine liver CT protocol equilibrium phase data : Preliminary experience. Eur J Radiol. 103, 2018, 99-104.
P.52 掲載の参考文献
1) Hao, D. et al. MRI contrast agents : basic chemistry and safety. J Magn Reson Imaging. 36 (5), 2012, 1060-71.
2) Kanda, T. et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1 weighted MR images : relationship with increasing cumulative dose of a gadolinium based contrast material. Radiology. 270 (3), 2014, 834-41.
3) 日本医学放射線学会編. "消化器領域の標準的撮像法". 画像診断ガイドライン 2016年版. 東京, 金原出版, 2016, 260-8.
4) Onishi, H. et al. Hypervascular hepatocellular carcinomas : detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol. 22 (4), 2012, 845-54.
5) Asayama, Y. et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma : radiologic-pathologic correlation with special reference to bile production Eur J Radiol. 80 (3), 2011, e243-8.
6) Niekel, MC. et al. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT : a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 257 (3), 2010, 674-84.
7) Grazioli, L. et al. Hepatocellular adenoma and focal nodular hyperplasia : value of gadoxeticacid-enhanced MR imaging in differential diagnosis. Radiology. 262 (2), 2012, 520-9.
P.59 掲載の参考文献
1) Miyayama, S. et al. Efficacy of cone-beam computed tomography during transcatheter arterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol. 29 (6), 2011, 371-7.
2) Michels, NA. Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg. 112 (3), 1966, 337-47.
3) Covey, AM. et al. Variant hepatic arterial anatomy revisited : digital subtraction angiography performed in 600 patients. Radiology. 224 (2), 2002, 542-7.
4) Matsui, O. et al. Hepatocelluar nodules in liver cirrhosis : hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging. 36 (3), 2011, 264-72.
5) Johnson, CM. Computed tomography and angiography of cavernous hemangiomas of the liver. Radiology. 138 (1), 1981, 115-21.
6) 大野健次ほか. 肝限局性結節性過形成 (FNH) の画像診断 CT像と血管造影における肝細胞癌 (HCC) との比較. 日本医学放射線学会雑誌. 51 (5), 1991, 479-86.
7) Kiyosue, H. Transcatheter obliteration of gastric varices : Part 2. Strategy and techniques based on hemodynamic features. Radiographics. 23 (4), 2003, 921-37.

[3] C型肝炎の診断と治療

P.64 掲載の参考文献
1) Sakamoto, N. et al. New therapeutic approaches to hepatitis C virus. J Gastroenterol. 44 (7), 2009, 643-9.
2) Kumada, H. et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59 (6), 2014, 2083-91.
3) Kumada, H. et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 53 (4), 2018, 566-75.
4) Izumi, N. et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 12 (4), 2018, 356-67.
5) Doi, A. et al. Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology. 68 (1), 2018, 380-3.
6) Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41 (10), 2009, 1105-9.
7) Thomas, DL. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 461 (7265), 2009, 798-801.
8) Mizokami, M. et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis. 15 (6), 2015, 645-53.
9) Fellay, J. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 464 (7287), 2010, 405-8.
P.71 掲載の参考文献
1) 鎌江伊三夫ほか. 日本におけるC型肝炎の疫学, 治療および医療経済. 肝臓. 55 (10), 2014, 589-603.
2) 田中純子ほか. わが国におけるB型肝炎・C型肝炎ウイルスキャリアの現状. 医学のあゆみ. 262 (14), 2017, 1221-6.
3) 和田清ほか. 薬物乱用・依存者におけるHIV感染と行動のモニタリングに関する研究 (2017年). 「薬物乱用・依存者, 性感染症患者のHIV 感染状況及び内外のHIV流行等の動向に関する研究」分担研究報告書. 2018.
4) 新田孝作ほか. わが国の慢性透析療法の現況 (2018年12月31日現在). 日本透析医学会雑誌. 52 (12), 2019, 679-754.
5) Shiraki, K. et al. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr Int. 50 (1), 2008, 138-40.
6) Terrault, NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 36 (5 Suppl 1), 2002, S99-105.
7) Jackel, E. et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 345 (20), 2001, 1452-7.
8) Nomura, H. et al. Short-term interferon-alfa therapy for acute hepatitis C : a randomized controlled trial. Hepatology. 39 (5), 2004, 1213-9.
9) Martinello, M. et al. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 15 (7), 2018, 412-24.
10) Thomas, DL. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 461 (7265), 2009, 798-801.
11) Ruiz-Extremera, A. et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 53 (6), 2011, 1830-8.
12) Westbrook, RH. et al. Natural history of hepatitis C. J Hepatol. 61 (1 Suppl), 2014, S58-68.
13) 日本肝臓学会編. 慢性肝炎の治療ガイド 2006. 東京, 文光堂, 2006.
14) Yoshida, H. et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 131 (3), 1999, 174-81.
15) Tong, MJ. et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332 (22), 1995, 1463-6.
16) Poynard, T. et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349 (9055), 1997, 825-32.
17) Everhart, JE. et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 137 (2), 2009, 549-57.
18) Kasahara A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 27 (5), 1998, 1394-402.
19) Ikeda K, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C : A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 29 (4), 1999, 1124-30.
20) Tanaka, J. et al. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol. 70 (3), 2003, 378-86.
21) Kasahara, A. et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 11 (2), 2004, 148-56.
22) Seeff, LB. et al. Natural history of chronic hepatitis C. Hepatology. 36 (5 Suppl 1), 2002, S35-46.
23) Tremolada, F. et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 16 (3), 1992, 273-81.
24) Kenny-Walsh, E. et al. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 340 (16), 1999, 1228-33.
25) Weise, M. et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol. 43 (4), 2005, 590-8.
26) Seeff, LB. et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 132 (2), 2000, 105-11.
P.78 掲載の参考文献
P.81 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会編. C型肝炎治療ガイドライン. 第8版. 2020. http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c (2021年5月20日閲覧)
P.94 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会編. C型肝炎治療ガイドライン. 第8版. 2020. http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c (2021年5月20日閲覧)
2) Takehara, T. et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol. 54 (1), 2019, 87-95.
3) 厚川正則ほか. 慢性腎臓病合併C型慢性肝炎に対するエルバスビル・グラゾプレビル療法の有効性と安全性. 肝臓. 58 (12), 2017, 678-80.
5) Mizuochi, T. et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period : a nationwide survey in Japan. J Gastroenterol. 53 (3), 2018, 419-26.
6) 肝炎等克服実用化研究事業「小児期のウイルス性肝炎の病態解明と治療の標準化に関する研究」班. C型肝炎母子感染小児の診療ガイドライン. 2020.
7) Jonas, MM. et al. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus : Part 1 of the DORA Study. Hepatology. 71 (2), 2020, 456-62.
P.99 掲載の参考文献
1) Trauner, M. Review article : mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther. 13 (8), 1999, 979-96.
2) Omata, M. et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut. 56 (12), 2007, 1747-53.
3) 永山和宣ほか. "消化管・肝疾患". ステロイド薬の選び方・使い方ハンドブック. 東京, 羊土社, 2007, 213-38.
4) Arase, Y. et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 79 (8), 1997, 1494-500.
5) 石川哲也. グリチルリチン製剤. モダンフィジシャン. 28 (1), 2008, 76-9.
6) 熊田博光. 肝硬変を含めたウイルス性肝疾患の治療の標準化に関する臨床的研究 : 厚生労働科学研究費補助金肝炎等克服緊急対策研究事業 (肝炎分野) 総括研究報告書. 2009.
7) Iino, S. et al. Therapeutic effects of stronger neominophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res. 19 (1), 2001, 31-40.
8) Hayashi, H. et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic hepatitis C and excess hepatic iron. Am J Gastroenterol. 89 (7), 1994, 986-8.
9) 佐竹正博ほか. 採血により献血者に起こる副作用・合併症の解析 : 平成14年の全国データから. 平成15年度厚生労働科学研究費補助金 (医薬品等医療技術リスク評価研究事業) 分担研究報告書. 40-6.
10) 厚生労働省医薬食品局血液対策課. 平成19年度血液事業報告.
11) Patek, AJ. et al. Treatment of cirrhosis of the liver by a nutritious diet and supplements rich in vitamin B complex. J Clin Invest. 20 (5), 1941, 481-505.

[4] B型肝炎の診断と治療

P.106 掲載の参考文献
1) Ghany, M. et al. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 132 (4), 2007, 1574-85.
3) Hussain, Z. et al. "1. Introduction". Genomic Heterogeneity of Hepatitis Viruses (A-E) : Role in Clinical Implications and Treatment. Practical Management of Chronic viral Hepatitis. ed. Serviddeo, G. Rijeka, InTech, 2013.
P.109 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会編. B型肝炎治療ガイドライン. 第3.4. 2020. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b.html (2021年5月20日閲覧)
2) 加藤道夫ほか. HBVマーカーと発癌リスクよりみたHBVキャリアのステージ分類 : 適切な抗ウイルス治療の選択に向けて. 肝臓. 45 (11), 2004, 581-8.
P.113 掲載の参考文献
1) 白木和夫. HBV母子感染の疫学. 肝・胆・膵. 13 (3), 1986, 493-501.
3) 稲葉憲之. 肝炎ウイルスと母子感染対策 : とくにB, C型肝炎ウイルスについて. 産婦人科治療. 90, 2005, 617-23.
4) 和田宏来. B型肝炎ウイルス感染症. 小児科診療. 74 (9), 2011, 1413-7.
5) 森島恒雄. ウイルス母子感染防止に関する調査研究「わが国におけるB型肝炎母子垂直感染防止の現状と問題点 : 全国調査から」. 平成13年度厚生科学研究費補助金子ども家庭総合研究事業分担研究報告書.
6) 日本小児科学会. B型肝炎ウイルス母子感染のための新しい指針. https://www.jpeds.or.jp/uploads/files/HBV20131218.pdf (2021年5月20日閲覧)
7) 須磨崎亮. 小児におけるB型肝炎の水平感染の実態把握とワクチン戦略の再構築に関する研究. 平成27年度厚生労働科学研究費補助金 肝炎等克服対策研究事業研究報告書.
9) 佐賀県B型肝炎集団発生調査対策委員会. 保育所における急性ウイルス性肝炎 (B型) の集団発生について. https://www.kansen.pref.saga.jp/kisya/kisya/hb/Bkan140910.pdf (2021年5月20日閲覧)
10) 白木和夫. わが国におけるB型肝炎母子感染防止の経緯とuniversal vaccination の必要性について. 小児感染免疫. 21 (2), 2009, 149-57.
11) 田尻仁. 小児におけるHBV水平感染の実態とB型肝炎ワクチン定期接種化の意義. 日本小児科学会雑誌. 121 (1), 2017, 51-9.
P.120 掲載の参考文献
P.125 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会編. B型肝炎治療ガイドライン. 第3.4版. 2021. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b.html (2021年5月20日閲覧)
3) ペグインターフェロン-α-2a製剤添付文書. 中外製薬. 2019年10月改訂.
4) Lau, GK. et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 351 (26), 2005, 2682-95.
5) Marcellin, P. et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. 150 (1), 2016, 134-44.
6) Serfaty, L. et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone : results of a pilot study. Hepatology. 34 (3), 2001, 573-7.
7) Matsumoto, A. et al. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol. 55 (10), 2020, 977-89.
P.134 掲載の参考文献
1) Yatsuji, H. et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy : two-year follow-up. J Hepatol. 48 (6), 2008, 923-31.
2) Ono, A. et al. Long-term continuous entecavir therapy in nucleos (t) ide-naive chronic hepatitis B patients. J Hepatol. 57 (3), 2012, 508-14.
3) Suzuki, F. et al. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol. 52 (5), 2017, 641-51.
4) Kumada, H. et al. Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos (t) ide analogs. Hepatol Res. 47 (10), 2017, 1032-41.
5) Koike, K. et al. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patient. Hepatol Res. 48 (1), 2018, 59-68.
6) Murakami, E. et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 59 (6), 2015, 3563-9.
7) Agarwal, K. et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 62 (3), 2015, 533-40.
8) 日本肝臓学会肝炎診療ガイドライン作成委員会. B型肝炎治療ガイドライン. 第3.4.版. 2021. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b.html (2021年5月20日閲覧)
9) Suzuki, F. et al. Long-term outcome of entecavir treatment of nucleos (t) ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol. 54 (2), 2019, 182-93.
10) Suzuki, F. et al. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol. 49 (6), 2014, 1094-104.
11) Fontana, RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 49 (6 Suppl), 2009, 185-95.
12) Lampertico, P. et al. Review article : long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patient. Aliment Pharmacol Ther. 44 (1), 2016, 16-34.
13) Tanaka, M. et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 49 (3), 2014, 470-80.
14) Hiramatsu, R. et al. Bone histology of two cases with osteomalacia related to low-dose adefovir. Intern Med. 55 (20), 2016, 3013-9.
15) Liaw, YF. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 351 (15), 2004, 1521-31.
16) Hosaka, T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 58 (1), 2013, 98-107.

[5] HIV重複感染患者の管理

P.155 掲載の参考文献
1) 厚生労働省エイズ動向委員会. 令和元 (2019) 年エイズ発生動向-概要-. 2019. https://api-net.jfap.or.jp/status/japan/nenpo.html (2021年5月20日閲覧)
2) 厚生労働省エイズ動向委員会. サーベイランスのためのHIV感染症/AIDS診断基準. https://api-net.jfap.or.jp/library/data/law/images/070808_03.pdf (2021年5月20日閲覧)
3) UNAIDS. FACT SHEET-WORLD AIDS DAY 2020. https://www.unaids.org/en/resources/fact-sheet (2021年5月20日閲覧)
4) 日本エイズ学会・日本臨床検査医学会. 診療におけるHIV-1/2感染症の診断ガイドライン 2020版. https://jaids.jp/news/hiv-1-22020/ (2021年5月20日閲覧)
5) Kondo, M. et al. Comparative evaluation of the Geenius HIV 1/2 Confirmatory Assay and the HIV-1 and HIV-2 Western blots in the Japanese population. PLoS One. 13 (10), 2018, e0198924.
6) Nagashima, M. et al. Examination of Efficient HIV Confirmatory Testing Protocols Using an HIV-1/2 Antibody Differentiation Assay. Jpn J Infect Dis. 73 (2), 2020, 173-5.
7) Delaney, KP. et al. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1 : Implications for Interpreting Test Results and Retesting After Exposure. Clin Infect Dis. 64 (1), 2017, 53-9.
8) Lodi, S. et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds < 200, < 350, and < 500 Cells/mm3 : assessment of need following changes in treatment guidelines. Clin Infect Dis. 53 (8), 2011, 817-25.
9) Watanabe, D. et al. Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan : a retrospective observational study. AIDS Res Ther. 12, 2015, 19.
10) Song, R. et al. Using CD4 Data to Estimate HIV Incidence, Prevalence, and Percent of Undiagnosed Infections in the United States. J Acquir Immune Defic Syndr. 74 (1), 2017, 3-9.
11) Kahn, JO. et al. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 339 (1), 1998, 33-9.
13) 日本医療研究開発機構エイズ対策実用化研究事業「ART早期化と長期化に伴う日和見感染症への対処に関する研究」班. HIV感染症に伴う日和見合併症の全国実態調査-全国HIV診療拠点病院アンケート調査2018年. http://after-art.umin.jp/enq_hiyorimi.html (2021年5月20日閲覧)
14) TEMPRANO ANRSSG. et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 373 (9), 2015, 808-22.
15) INSIGHT STARTSG. et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 373 (9), 2015, 795-807.
16) Cohen, MS. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 365 (6), 2011, 493-505.
17) 厚生労働行政推進調査事業費補助金エイズ対策政策研究事業「HIV感染症及びその合併症の課題を克服する研究」班. 抗HIV治療ガイドライン. 2020. https://www.haart-support.jp/guideline.htm (2021年5月20日閲覧)
18) Eyster, ME. et al. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 115 (10), 1991, 764-8.
19) van de Laar, TJ. et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 196 (2), 2007, 230-8.
20) van de Laar, TJ. et al. Acute hepatitis C in HIV-infected men who have sex with men : an emerging sexually transmitted infection. AIDS. 24 (12), 2010, 1799-812.
21) Nishijima, T. et al. Incidence and risk factors for incident Hepatitis C infection among men who have sex with men with HIV-1 infection in a large Urban HIV clinic in Tokyo. J Acquir Immune Defic Syndr. 65 (2), 2014, 213-7.
22) EACS Guidelines-v10.1. https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (2021年5月20日閲覧)
23) Watanabe, S. et al. Full-genome characterization of the RIVM-HAV16-090-like hepatitis A virus strains recovered from Japanese men who have sex with men, with sporadic acute hepatitis A. Hepatol Res. 49 (5), 2019, 521-30.
24) Tanaka, S. et al. Outbreak of hepatitis A linked to European outbreaks among men who have sex with men in Osaka, Japan, from March to July 2018. Hepatol Res. 49 (6), 2019, 705-10.
25) Koga, M. et al. Comparison of the Clinical Features of Hepatitis A in People Living with HIV between Pandemics in 1999-2000 and 2017-2018 in the Metropolitan Area of Japan. Jpn J Infect Dis. 73 (2), 2020, 89-95.
26) 西田恭治ほか. HIV感染症におけるウイルス性肝炎感染状況とA・B型肝炎ワクチンの効果に関する研究. 日本エイズ学会誌. 9, 2007, 30-5.
27) Gatanaga, H. et al. Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. Clin Infect Dis. 56 (12), 2013, 1812-9.
28) Riddell, J. et al. HIV Preexposure Prophylaxis : A Review. JAMA. 319 (12), 2018, 1261-8.
29) Rodger, AJ. et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 316 (2), 2016, 171-81.
30) Bavinton, BR. et al. Viral suppression and HIV transmission in serodiscordant male couples : an international, prospective, observational, cohort study. Lancet HIV. 5 (8), 2018, e438-47.
31) Watanabe, K. et al. Amebiasis in HIV-1-infected Japanese men : clinical features and response to therapy. PLoS Negl Trop Dis. 5 (9), 2011, e1318.
32) UNAIDS. PREVAILING AGAINST PANDEMICS BY PUTTING PEOPLE AT THE CENTRE. https://aidstargets2025.unaids.org/assets/images/prevailingagainst-pandemics_en.pdf (2021年5月20日閲覧)
33) Iwamoto, A. et al. The HIV care cascade : Japanese perspectives. PLOS ONE. 12 (3), 2017, e0174360.
34) Miyazaki, N. et al. The Prevalence of High Antiretro-viral Coverage and Viral Suppression in Japan : an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum. Jpn J Infect Dis. 70 (2), 2017, 158-60.
35) Matsuoka, S. et al. Estimating HIV-1 incidence in Japan from the proportion of recent infections. Prev Med Rep. 16, 2019, 100994.
36) Nishiura, H. Estimating the incidence and diagnosed proportion of HIV infections in Japan : a statistical modeling study. PeerJ. 7, 2019, e6275.
P.163 掲載の参考文献
1) Kodsi, BE. et al. Candida esophagitis : a prospective study of 27 cases. Gastroenterology. 71 (5), 1976, 715-9.
2) 岡田誠治ほか. エイズ関連悪性リンパ腫の現状と治療戦略. 臨床血液. 49 (10), 2008, 1490-8.
3) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 156 (2 Pt 2), 1997, S1-25.
P.167 掲載の参考文献
1) McMahon, MA. et al. The HBV drugentecavir-effects on HIV-1 replication and resistance. N Engl J Med. 356 (25), 2007, 2614-21.
2) 国立感染症研究所. HIV/AIDS 2020年IASR. 41 (10), 2020, 175-6.
3) McMahon, MA. et al. Brief Report : The HBV Drug Entecavir-Effects on HIV-1 Replication and Resistance. N Engl J Med. 356 (25), 2007, 2614-21.
4) 須磨崎亮. 小児におけるB型肝炎の水平感染の実態把握とワクチン戦略の再構築に関する研究. 厚生科学研究費補助金 肝炎等克服政策研究事業. 総合研究報告書 2015年度. 2016.
5) 田中純子. 肝炎ウイルス感染状況の把握及び肝炎ウイルス排除への方策に資する疫学研究. 厚生労働科学研究費補助金 疾病・障害対策研究分野 肝炎等克服政策研究事業. 総括研究報告書 2019年度. 2020.
6) 西田恭治ほか. HIV感染症におけるウイルス性肝炎感染状況とA・B型肝炎ワクチンの効果に関する研究. 日本エイズ学会誌. 9 (1), 2007, 30-5.
7) Koike, K. et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res. 38 (3), 2008, 310-4.
8) Tsutsumi, T. et al. Factors associated with clearance of hepatitis B virus surface antigen in patients infected with human immunodeficiency virus. Medicine. 99 (29), 2020, e21271.
9) Ito, K. et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 59 (1), 2014, 89-97.
10) Yanagimoto, S. et al. Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan : a retrospective multicenter analysis. J Infect Chemother. 18 (6), 2012, 883-90.
11) ClinicalInfo. DHHS : Guideline for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2019. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines (2021年5月20日閲覧)
12) ClinicalInfo. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, hepatitis B virus infection. last updated August 18. 2020.
13) Launay, O. et al. Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1 : A Randomized Controlled Trial. JAMA. 305 (14), 2011, 1432-40.
P.170 掲載の参考文献
1) Lin, W. et al. HIV increases HCV replication in a TGF-β 1-dependent manner. Gastroenterology. 134 (3), 2008, 803-11.
2) Tuyama, AC. et al. Human immunodeficiency virus (HIV) -1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression : implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology. 52 (2), 2010, 612-22.
3) Seki, E. et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med. 13 (11), 2007, 1324-32.
4) Woreta, TA. et al. Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus. Gastroenterology. 140 (3), 2011, 809-17.
5) 小池和彦. HIV感染症に合併する各種疾病に関する研究. 厚生労働科学研究費補助金エイズ対策研究事業. 平成19年度総括・分担研究報告書. 2008.
6) Platt, L. et al. Prevalence and burden of HCV coinfection in people living with HIV : a global systematic review and meta-analysis. Lancet Infect Dis. 16 (7), 2016, 797-808.
7) Nishijima, T. et al. Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo. J Acquir Immune DeficSyndr. 65 (2), 2014, 213-7.
8) Micallef, JM. Spontaneous viral clearance following acute hepatitis C infection : a systematic review of longitudinal studies. J Viral Hepat. 13 (1), 2006, 34-41.
9) Montes, ML. et al. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS. 31 (9), 2014, 1253-60.
10) Lambers, FA. et al. Alarming incidence of HCV re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV MSM. AIDS. 25 (17), 2011, F21-7.
11) Sarrazin, C. et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 64 (1), 2017, 44-52.

[6] 自己免疫性肝疾患の診断と治療

P.179 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班ホームページ. http://www.hepatobiliary.jp/ (2021年5月20日閲覧)
2) 厚生労働省難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班. 自己免疫性肝炎 (AIH) 診療ガイドライン (2016年) Ver 3. 2020.
3) Alvarez, F. et al. International Autoimmune Hepatitis Group Report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 31 (5), 1999, 929-38.
5) Suzuki, Y. et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab. 32 (4), 2014, 337.
P.186 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班ホームページ. http://www.hepatobiliary.jp/ (2021年5月20日閲覧)
2) 厚生労働省難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班. 原発性胆汁性胆管炎 (PBC) 診療ガイドライン (2017年). 2017.
3) Scheuer, PJ. Primary biliary cirrhosis. Proc R Soc Med. 60 (12), 1967, 1257-60.
6) 厚生労働省難治性疾患克服研究事業「難治性の肝・胆道疾患に関する調査研究」班編. 原発性胆汁性肝硬変 (PBC) の診療ガイドライン. 2012.
P.191 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班ホームページ. http://www.hepatobiliary.jp/ (2021年5月20日閲覧)
2) 日本膵臓学会・厚生労働科学研究費補助金 (難治性疾患等政策研究事業) 「IgG4関連疾患の診断基準並びに治療指針の確立を目指す研究」班. 報告 自己免疫性膵炎臨床診断基準 2018 (自己免疫性膵炎臨床診断基準 2011改訂版). 膵臓. 33 (6), 2018, 902-13.
3) 厚生労働省「IgG4関連全身硬化性疾患の診断法の確立と治療方法の開発に関する研究」班編. IgG4関連硬化性胆管炎臨床診断基準 2012. 胆道. 26 (1), 2012, 59-63.
4) Lindor, KD. et al. "Primary sclerosing cholangitis". Schiff's Diseases of the Liver, Ninth Edition. Schiff, L. et al. ed. Philadelphia, JB Lippincott, 2003, 673-84.
5) 厚生労働省「難治性肝・胆道疾患に関する調査研究」班 (滝川班) 編. 2016年原発性硬化性胆管炎診断基準.
6) Nakazawa, T. et al. The 2016 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol. 52 (7), 2017, 838-44.
7) 水野卓ほか. PSCのステント治療. 臨牀消化器内科. 29 (11), 2014, 1449-54.

[7] アルコール性肝障害の診断と治療

P.203 掲載の参考文献
1) 国税庁課税部酒税課. 酒のしおり. 2020. 令和2年3月.
2) 谷合麻紀子. アルコール性肝障害の現況. 肝臓. 59 (7), 2018, 312-8.
3) 武内重五郎ほか. わが国におけるアルコール性肝障害の実態-全国集計の成績から-. 日本消化器学会雑誌. 76 (11), 1979, 2178-84.
4) Gao, B. et al. Alcoholic liver disease : pathogenesis and new therapeutic targets. Gastroenterology. 141 (5), 2011, 1572-85.
5) 藤田尚巳, 竹井謙之. アルコール性肝障害. 臨床と研究. 90 (2), 2013, 176-82.
6) Higuchi, S. et al. Polymorphisms of ethanol-oxidizing enzymes in alcoholics with inactive ALDH2. Hum Genet. 97 (4), 1996, 431-4.
7) Tsutsumi, M. et al. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology. 10 (4), 1989, 437-46.
8) Lu, Y. et al. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology. 47 (5), 2008, 1483-94.
9) 堀江義則ほか. 本邦におけるアルコール性肝障害の実態. 日本消化器病学会誌. 112 (9), 2015, 1630-40.
10) アルコール医学生物学研究会. JASBRAアルコール性肝障害診断基準 2011年版 (2021年小改訂), 旭川, アルコール医学生物学研究会, 2012.
11) 堀江義則ほか. アルコール性肝炎重症度スコアの有用性の検証と治療介入による予後への影響についての検討. 肝臓. 55 (1), 2014, 22-32.
12) Nakano, M. et al. Perivenular fibrosis in alcoholic liver injury : ultrastructure and histologic progression. Gastroenterology. 83 (4), 1982, 777-85.
13) Suzuki, S. et al. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. 43 (10), 2013, 1020-31.
14) European Association for the Study of Liver. EASL clinical practical guidelines : managementof alcoholic liver disease. J Hepatol. 57 (2), 2012, 399-420.
15) O'Shea, RS. et al. Alcoholic liver disease. Hepatology. 51 (1), 2010, 307-28.
16) Bush, K. et al. The AUDIT alcohol consumption questions (AUDIT-C) : an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 158 (16), 1998, 1789-95.
17) Egawa, H. et al. Significance of pre-transplant abstinence on harmful alcoholrelapse after liver transplantation for alcoholiccirrhosis in Japan. Hepatol Res. 44 (14), 2014, E428-36.
18) 日本アルコール・アディクション医学会ほか. 日本アルコール関連問題学会. 新アルコール・薬物使用障害の診断治療ガイドラインに基づいたアルコール依存症の診断治療の手引き. 第1版. 2018, 14. https://www.j-arukanren.com/pdf/20190104_shin_al_yakubutsu_guide_tebiki.pdf (2021年5月20日閲覧)

[8] 脂肪肝・脂肪肝炎の診断と治療

P.215 掲載の参考文献
1) Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease : practical guidance from the American Association for the Study of Liver Disease. Hepatology. 67 (1), 2018, 328-57.
2) 日本消化器病学会・日本肝臓学会編. NAFLD/NASH診療ガイドライン 2020. 改訂第2版. 東京, 南江堂, 2020.
3) Ludwig, J. et al. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc. 55 (7), 1980, 434-8.
4) Schaffner, F. et al. Nonalcoholic fatty liver disease. Prog Liver Dis. 8, 1986, 283-98.
5) Angulo, P. et al. Liver fibrosis, but not other histologic features is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 149 (2), 2015, 389-97.
6) Dulai, PS. et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease : systemic review and meta-analysis. Hepatology. 65, 2017, 1557-65.
8) Vilar-Gomez, E. et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : a multi-national chohort study. Gastroenterology. 155 (2), 2018, 443-57.
9) GBD 2015 Obesity Collaborators. et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 377 (1), 2017, 13-27.
10) Ogurtsova, K. et al. IDF diabetes atlas : global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 128, 2017, 40-50.
11) Younossi, ZM. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64, 2016, 73-84.
12) Hamaguchi, M. et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 143 (10), 2005, 722-8.
13) Eguchi, Y. et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan : a multicenter large retrospective study. J Gastroenterol. 47 (5), 2012, 586-95.
14) Nishioji, K. et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol. 50 (1), 2015, 95-108.
15) Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2-30. J Hepatol. 69 (4), 2018, 896-904.
16) Okanoue, T. et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 26 (Suppl 1), 2011, 153-62.
17) Seko, Y. et al. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with nonalcoholic fatty liver disease. Hepatology Research. 48 (3), 2018, E42-51.
18) Shima, T. et al : Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol. 48 (4), 2013, 515-25.
19) Nakahara, T. et al. Japan Study Group of Nonalcoholic Fatty Lier Disease : Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 49 (11), 2014, 1477-84.
20) Kojima, S. et al. Increase in the prevalence of fatty liver in Japan over the past 12 years : analysis of clinical background. J Gastroenterol. 38 (10), 2003, 954-61.
21) Jimba, S. et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 22 (9), 2005, 1141-5.
22) Marchesini, G. et al. Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. Am J Med. 107 (5), 1999, 450-5.
23) Fujii, H. et al. HOMA-IR : An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 34 (8), 2019, 1390-5.
24) Hamaguchi, E. et al. Histological course of nonalcoholic fatty liver disease in Japanese patients : tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 33 (2), 2010, 284-6.
25) 添田光太郎ほか. 糖尿病とNASH・NAFLD. 臨床消化器内科. 33 (1), 2017, 45-52.
26) Donnelly, KL. et al. Source of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 115 (5), 2005, 1343-51.
27) Charlton, M. et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35 (4), 2002, 898-904.
28) Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic-steatohepatitis. Hepatology. 45 (6), 2007, 1366-74.
29) Hosooka, T. et al. The PDK1-FoxO1 signaling in adipo-cytes controls systemic insulin sensitivity through the 5-lipoxygemnase-leukotriene B4 axis. Proc Natl Acad Sci USA. 117 (21), 2020, 11674-84.
30) Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 40 (12), 2008, 1461-5.
31) Kawaguchi, T. et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japan. PLoS One. 7 (6), 2012, e38322.
32) Seko, Y. et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease : association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatol Res. 47 (11), 2017, 1083-92.
33) Bruschi, FV. et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 65 (6), 2017, 1875-90.
34) Day, C. et al. Steatohepatitis : A Tale of Two "Hits". Gastroenterology. 114 (4), 1998, 842-5.
35) Tilg, H. et al. Evolution of inflammation in nonalcoholic fatty liver disease : the multiple parallel hit hypothesis. Hepatology. 52 (5), 2010, 1836-46.
36) Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement. J Hepatol. 73 (1), 2020, 202-9.
37) Matteoni, CA. et al. Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity. Gastroenterology. 116 (6), 1999, 1413-9.
38) Brunt, EM. et al. Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94 (9), 1999, 2467-74.
39) Kleiner, DE. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41 (6), 2005, 1313-21.
40) Xiao, G. et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease : A meta-analysis. Hepatology. 66 (5), 2017, 1486-501.
41) Vilar-Gomez, E. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 149 (2), 2015, 367-78.
42) Sanyal, AJ. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362 (18), 2010, 1675-85.
43) Sato, K. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease : a meta-analysis of randomized controlled trials. Nutrition. 31 (7-8), 2015, 923-30.
44) Armstrong, MJ. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) : a multicenter, double-blind, randomized, placebo-controlled phase 2 study. Lancet. 387 (10019), 2016, 679-90.

[9] 薬物性肝障害の診断と治療

P.224 掲載の参考文献
1) Benichou, C. et al. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 11 (2), 1990, 272-6.
2) Sgro, C. et al. Incidence of drug-induced hepatic injuries : a French population-based study. Hepatology. 36 (2), 2002, 451-5.
3) Bjornsson, ES. et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterol. 144 (7), 2013, 1419-25.
4) Roth, SE. et al. Next Generation DILI Biomarkers : Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development. Clin Pharmacol Ther. 107 (2), 2020, 333-46.
5) Daly, AK. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 41 (7), 2009, 816-9.
6) McGill, MR. et al. Biomarkers of drug-induced liver injury : progress and utility in research, medicine, and regulation. Expert Rev Mol Diagn. 18 (9), 2018, 797-807.
7) 滝川一ほか. DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓. 46 (2), 2005, 85-90.
8) 日本肝臓学会. 薬物性肝障害診断基準. https://www.jsh.or.jp/medical/guidelines/medicalinfo/mtphama (2021年5月20日閲覧)
9) 滝川一ほか. 薬物性肝障害とリンパ球刺激試験. 肝臓. 42 (2), 2001, 445-7.
10) 武藤美香ほか. 薬疹におけるリンパ球刺激試験の診断的価値についての検討. 日本皮膚科学会雑誌. 110 (10), 2000, 1543-8.
11) Nakao, M. et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol. 53 (6), 2018, 752-69.
12) Sugawara, K. et al. Acute liver failure in Japan : definition, classification, and prediction of outcome. J Gastroenterol. 47 (8), 2012, 849-61.
13) Reuben, A. et al. Acute Liver Failure Study Group. Drug-induced acute liver failure ; results of a US multicenter, prospective study. Hepatology. 52 (6), 2010, 2065-76.
14) U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry Drug-Induced Liver Injury : Premarketing Clinical Evaluation. 2009. https://www.fda.gov/media/116737/download (2021年5月20日閲覧)
15) Robles-Diaz, M. et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterol. 147 (1), 2014, 109-18.
16) Ortega-Alonso, A. et al. Chronic liver injury induced by drugs and toxins. J Dig Dis. 19 (9), 2018, 514-21.
17) Polson, J. et al. American Association for the Study of Liver Disease. AASLD position paper ; the management of acute liver failure. Hepatology. 41 (5), 2005, 1179-97.
18) Bohan, TP. et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 56 (10), 1405-9.
19) Bjornsson, ES. et al. Drug-induced autoimmune hepatitis : clinical characteristics and prognosis. Hepatology. 51 (6), 2010, 2040-8.
20) 日本臨床腫瘍学会編. がん免疫療法ガイドライン. 第2版. 東京, 金原出版, 2019, 162.
21) Haanen, JBAG. et al. Management of toxic from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (suppl 4), 2017, iv, 119-42.
22) National Comprehensive Cancer Network NCCN Clinical Practice Guideline in Oncology, Management of Immunotherapy-Related Toxicities. Ver.1. 2020. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf (2021年5月20日閲覧)
23) 医薬品医療機器総合機構. 薬物性肝障害. 重篤副作用疾患別対応マニュアル. https://www.pmda.go.jp/safety/info-services/drugs/adr-info/manuals-for-hc-pro/0001.html (2021年5月20日閲覧)
24) 医薬品医療機器総合機構. 医薬品副作用等情報. https://www.pmda.go.jp/safety/info-services/drugs/adr-info/0001.html (2021年5月20日閲覧)
25) 柿崎暁ほか. プレドニゾロンのジェネリック医薬品への変更により増悪した自己免疫性肝炎の1例. 日本消化器病学会雑誌. 106, 2009, 1488-93.

[10] 肝硬変の治療

P.233 掲載の参考文献
1) 日本肝臓学会編. 慢性肝炎・肝硬変の診療ガイド 2019. 東京, 文光堂, 2019.
2) 日本肝臓学会編. "セッションの概要について". 肝硬変の成因別実態 2018. 東京, 医学図書出版, 2019, 1-2.
3) 岡上武ほか. "わが国の肝硬変の現状". 肝硬変の成因別実態 1998. 小林健一ほか編. 東京, 中外医学社, 1997, 1-5.
4) 青柳豊ほか. "集計 本邦の肝硬変の成因と現状 第44回日本肝臓学会総会主題ポスター「肝硬変の成因別実態」のまとめ". 肝硬変の成因別実態 2008. 恩地森一監. 東京, 中外医学社, 2008, 1-10.
5) 鈴木康秋ほか. "我が国における非B非C肝硬変の実態. 第15回日本肝臓学会大会特別企画「主題ポスター討論 : 我が国における非B非C肝硬変の実態調査」の集計報告". 我が国における非B非C肝硬変の実態調査 2011. 高後裕監. 北海道, 響文社, 2012, 6-16.
6) 泉並木ほか. "肝硬変の成因別実態 2014 全国集計". 肝硬変の成因別実態 2014. 泉並木監. 東京, 医学図書出版, 2015, 146-8.
7) 日本消化器病学会・日本肝臓学会編. 肝硬変診療ガイドライン 2020. 改訂第3版. 東京, 南江堂, 2020.
P.241 掲載の参考文献
1) Schneeweiss, B. et al. Energy metabolism in patients with acute and chronic liver disease. Hepatology. 11 (3), 1990, 387-93.
2) Alberino, F. et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 17 (6), 2001, 445-50.
3) European Association for the study of the Liver. EASL, Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 70 (1), 2019, 172-93.
4) Muto, Y. et al. Effect of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 3 (7), 2005, 705-13.
5) Muto, Y. et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 35 (3), 2006, 204-14.
6) Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the study of Liver Diseases. Hepatology. 67 (1), 2018, 328-57.
7) Wu, D. et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 559 (7715), 2018, 637-41.
8) 日本消化器病学会・日本肝臓学会編. 肝硬変診療ガイドライン 2020. 改訂第3版. 東京. 南江堂. 2020.
9) 日本消化器病学会編. 肝硬変診療ガイドライン 2015. 改訂第2版. 東京. 南江堂. 2015.
10) 日本肝臓学会編. 肝疾患におけるサルコペニア判定基準 (第1版). 2016. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/sarcopenia (2021年5月20日閲覧)
11) Plauth, M. et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 38, 2019, 485-521.
12) Suzuki, K. et al. Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatol Res. 42 (7), 2012, 621-6.
13) Chen, CJ. et al. Significant effects of late evening snack on liver functions in patients with liver cirrhosis : A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 34 (7), 2019, 1143-52.
14) Guo, YJ. et al. Effects of Late Evening Snack on Cirrhotic Patients : A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 1, 2018, 9189062.
15) Ijichi, C. et al. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Biophys Res Commun. 303 (1), 2003, 59-64.
16) 市田文弘ほか. 肝性脳症を伴う非代償性肝硬変患者に対する特殊アミノ酸経腸栄養剤の臨床的研究. 肝臓. 29 (8), 1988, 1051-61.
17) Gluud, LL. et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 25 (2), 2015, CD001939.
18) Elkrief, L. et al. Diabetes mellitus in patients with cirrhosis : clinical implications and management. Liver Int. 36 (7), 2016, 936-48.
19) Chen, J. et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases : a meta-analysis of cohort studies. Eur J Cancer Prev. 24 (2), 2015, 89-99.
20) アミノレバン(R) EN配合散 添付文書. 第11版. 大塚製薬. 2017年11月改訂.
21) ヘパン(R) ED配合内用剤 添付文書. 第6版. EAファーマ. 2016年4月改訂.
22) リーバクト(R) 配合顆粒 添付文書. 第17版. EAファーマ. 2016年4月改訂.
23) Singh, S. et al. Anti-diabetic medications and the risk of hepatocellular cancer : a systematic review and metaanalysis. J Gastroenterol. 108 (6), 2013, 881-91.
24) Reding, P. et al. Oral zinc supplementation improves hepatic encephalopathy. Results of randomized controlled trial. Lancet. 2 (8401), 1984, 493-5.
25) Haussinger, D. Nitrogen metabolism in liver ; Structural and functional organization and physiological relevance. Biochem J. 267 (2), 1990, 281-90.
26) Kojima-Yuasa, A. et al. Involvement of intracellular glutathione in zinc deficiency-induced activation of hepatic stellate cells. Chem Biol Interact. 146 (1), 2003, 89-99.
27) Hosui, A, et al. Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma. Nutrients. 10 (12), 2018, 1955.
P.248 掲載の参考文献
1) 加藤章信ほか. 肝性脳症 : 診断・検査. 日本消化器病学会雑誌. 104 (3), 2007, 344-51.
2) Albrecht, J. et al. Hepatic encephalopathy : Molecular mechanisms underlying the clinical syndrome. J Neurological Science. 170 (2), 1999, 138-46.
3) Katayama, K. Zinc and protein metabolism in chronic liver diseases. Nutr Res. 74, 2020, 1-9.
4) Malaguarnera, M. et al. Acetyl- L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 46 (6), 2011, 750-9.
5) 日本消化器病学会・日本肝臓学会編. "BQ3-2 就寝前エネルギー投与は肝硬変の病態に影響するか? ". 肝硬変診療ガイドライン 2020. 改訂第3版. 2020, 17.
6) 日本消化器病学会・日本肝臓学会編. "BQ4-14 肝性脳症に対して分岐鎖アミノ酸 (BCAA) 製剤は有用か? ". 肝硬変診療ガイドライン 2020. 改訂第3版. 2020, 17.
P.256 掲載の参考文献
1) 日本門脈圧亢進症学会. 門脈圧亢進症取扱い規約. 改訂第3版. 東京, 金原出版, 2013, 37-8.
2) Matsumoto, A. et al. Three-dimensional portography using multislice helical CT is clinically useful for management of gastric fundic varices. AJR Am J Roentgenol. 176 (4), 2001, 899-905.
3) Matsuo, M. et al. Esophageal varices : diagnosis with gadolinium-enhanced MR imaging of the liver for patients with chronic liver damage. AJR Am J Roentgenol. 180 (2), 2003, 461-6.
4) Abraldes, JG. Medical management of variceal bleeding in patients with cirrhosis. Can J Gastroenterol. 18 (2), 2004, 109-13.
5) 日本消化器病学会・日本肝臓学会編. 肝硬変診療ガイドライン 2020 (改訂第3版). 東京, 南江堂, 2020, 50-64.
7) Merkel, C. et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 127 (2), 2004, 476-84.
8) Garcia-Pagan, JC. et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed : a double-blind RCT. Hepatology. 37 (6), 2003, 1260-6.
9) Liu, JS. et al. Comparison of emergency endoscopic variceal ligation plus octride or octride alone for acute esophageal variceal bleeding. Chin Med J (Engl). 122 (24), 2009, 3003-6.
10) Lo, GH. et al. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut. 58 (9), 2009, 1275-80.
11) 日本消化器内視鏡学会監. 消化器内視鏡ガイドライン. 第3版. 東京, 医学書院, 2006, 360p.
14) Tripathi, D. et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 50 (3), 2009, 825-33.
15) Funakoshi, N. et al. Benefit of combination beta-blocker and endoscopic treatment to prevent variceal rebleeding : a meta-analysis. World J Gastroenterol. 16 (47), 2006, 5982-92.
16) Gotoh, Y. et al. Evaluation of endoscopic variceal ligation in prophylactic therapy for bleeding of oesophageal varices : a prospective, controlled trial compared with endoscopic injection sclerotherapy. J Gastroenterol Hepatol. 14 (3), 1999, 241-4.
17) Triantos, C. et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to make beta-bleckers : a randomized trial of ligation. Aliment Pharmacol Ther. 21 (12), 2005, 1435-43.
18) Iso, Y. et al. Repeated injection sclerotherapy is preferable to combined therapy with variceal ligation to avoid recurrence of esophageal varices : a prospective randomized trial. Hepatogastroenterology. 44 (14), 1997, 467-71.
20) Cipolletta, L. et al. Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices : preliminary results of a prospective randomized trial. Gastrointest Endosc. 56 (4), 2002, 467-71.
21) Mishra, SR. et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers : a randomized controlled trial. J Hepatol. 54 (6), 2011, 1161-7.
22) McCormack, TT. et al. Gastric lesions in portal hypertension : inflammatory gastritis or congestive gastropathy?. Gut. 26 (11), 1985, 1226-32.
23) Pan, WD. et al. Correlations of portal hypertensive gastropathy of hepatitis B cirrhosis with other factors. Hepatobiliary Pancreat Dis Int. 1 (4), 2002, 527-31.
24) Wagatsuma, Y. et. al. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology. 53 (68), 2006, 171-4.

[11] 肝癌の診断と治療

P.262 掲載の参考文献
1) Raul S, et al. Liver & intrahepatic bile ducts General WHO classification. PathologyOutlines.com. 2020. https://www.pathologyoutlines.com/topic/liverwhoclassification.html (2021年5月20日閲覧)
2) 日本肝癌研究会編. 原発性肝癌取扱い規約. 第6版補訂版. 東京, 金原出版, 2019, 46-57.
3) 日本肝癌研究会編. 原発性肝癌取扱い規約. 第6版補訂版. 東京, 金原出版, 2019, 17-8.
P.273 掲載の参考文献
1) 日本肝癌研究会追跡調査委員会. 第20回全国原発性肝癌追跡調査報告 (2008~2009). 肝臓, 60 (8), 2019, 258-93.
2) 日本肝癌研究会追跡調査委員会. 第22回全国原発性肝癌追跡調査報告 (2012~2013), 肝臓, 62 (5), 2021, 251-99.
3) 日本肝臓学会編. 肝癌診療ガイドライン 2017年版補訂版. 東京, 金原出版, 2017.
4) European Association for the Study of the Liver. EASL Clinical Practice Guidelines ; Management of hepatocellular carcinoma. J Hepatol. 69 (1), 2018, 182-236.
5) Marrero JA, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68 (2), 2018, 723-50.
6) Omata M, et al. Asian-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update. Hepatol Int. 11 (4), 2017, 317-70.
P.279 掲載の参考文献
1) 日本肝癌研究会追跡調査委員会. 第22回全国原発性肝癌追跡調査報告 (2012~2013). 肝臓. 62 (5), 2021, 251-299.
2) 日本肝臓学会編. 肝癌診療ガイドライン 2017年版補訂版. 東京, 金原出版, 2020.
3) Uka, K. et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 13 (3), 2007, 414-20.
4) Chen, CY. et al. High false negative rate of Tc-99m MDP whole-body bone scintigraphy in detecting skeletal metastases for patients with hepatoma. J Formos Med Assoc. 111 (3), 2012, 140-6.
5) 日本肝癌研究会編. 臨床・病理 原発性肝癌取扱い規約第6版補訂版. 東京, 金原出版, 2019.
6) Forner, A. et al. Hepatocellular carcinoma. Lancet. 391 (10127), 2018, 1301-14.
7) Arizumi,T. et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 4 (4), 2015, 253-62.
8) Bolondi, L. et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma : proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 32 (4), 2012, 348-59.
9) Kudo, M. et al. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies : proposal of modified Bolondi's subclassification (Kinki Criteria). Digest Dis. 33 (6), 2015, 751-8.
10) Johnson, PJ. et al. Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade. J Clin Oncol. 33 (6), 2015, 550-8.
11) Hiraoka, A. et al. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients : A Multicenter Analysis. Liver Cancer. 8 (2), 2019, 121-9.
P.286 掲載の参考文献
1) 春日井博志ほか. 多施設 (38施設) 調査に基づくラジオ波治療の現状と問題点. 肝臓. 44, 2003, 632-40.
2) Llovet, JM. et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 33 (5), 2001, 1124-9.
4) 日本肝癌研究会編. 原発性肝癌取扱い規約. 第6版補訂版. 東京, 金原出版, 2019.
5) 日本肝癌研究会追跡調査委員会. 第22回全国原発性肝癌追跡調査報告 (2012~2013). 肝臓. 62 (5), 2021, 251-299.
6) 日本肝臓学会編. 肝癌診療ガイドライン 2017年版補訂版. 東京, 金原出版, 2017.
7) 幕内雅敏. 肝硬変合併肝癌治療のStrategy. 外科診療. 29, 1987, 1530-6.
8) Yamanaka, N. et al. A prediction scoring system to select the surgical treatment of liver cancer. Further refinement based on 10 years of use. Ann Surg. 1994, 219 (4), 342-6.
9) Takasaki, T. et al. Predetermining postoperative hepatic function for hepatectomies. International surgery. 1980, 65 (4), 309-13.
10) Sato, M. et al. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma : a national survey of 54,145 patients. J Gastroenterol. 47 (10), 2012, 1125-33.
11) 永野浩昭ほか. 肝細胞癌切除後胸水貯留症例の検討. 日本消化器外科学会雑誌. 26 (1), 1993, 51-5.
12) Bruix, J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM) : a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16 (13), 2015, 1344-54.
13) Lok, AS. Does antiviral therapy prevent recurrence of hepatitis B virus-related hepatocellular carcinoma after curative liver resection? JAMA. 308 (18), 2012, 1922-4.
14) Nakajima, M. et al. Viral elimination is essential for improving surgical outcomes of hepatitis C virus-related hepatocellular carcinoma : Multicenter retrospective analysis. Ann Gastroenterol Surg. 4 (6), 2020, 710-20.
P.295 掲載の参考文献
1) 日本肝癌研究会編. 第20回全国原発性肝癌追跡調査報告書 (2008-2009). 2019.
2) 日本肝癌研究会編. 肝癌診療ガイドライン 2017年版補訂版. 東京, 金原出版, 2017.
3) Miyayama, S. et al. Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas : relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 18 (3), 2007, 365-76.
4) Irie, T. et al. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization : measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 36 (3), 2013, 706-13.
5) Matsumoto, T. et al. Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization. Minim Invasive Ther Allied Technol. 25 (1), 2016, 22-8.
6) 日本肝癌研究会編. 肝癌診療マニュアル. 第4版. 東京, 医学書院, 2020.
7) Hidaka, T. et al. Efficacy of combined bland embolization and chemoembolization for huge (> 10 cm) hepatocellular carcinoma. Minim Invasive Ther Allied Technol. 2020, 1-8. [online ahead of print]
8) Kitagawa, K. et al. Selective transcatheter hepatic arterial chemoembolization for hemobilia from hepatocellular carcinoma : report of three cases. J Vasc Interv Radiol. 10 (10), 1999, 1357-60.
9) Okazaki, M. et al. Intraperitoneal hemorrhage from hepatocellular carcinoma : emergency chemoembolization or embolization. Radiology. 180 (3), 1991, 647-51.
10) Takayasu, K. et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 175 (3), 2000, 699-704.
11) Kubota, K. et al. Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncol Rep. 24 (3), 2010, 727-32.
12) Lencioni, R. et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma : A systematic review of efficacy and safety data. Hepatology. 64 (1), 2016, 106-16.
14) Hatanaka, T. et al. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization : A retrospective cohort study. Hepatol Res. 48 (2), 2018, 165-75.
15) Lammer, J. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study. Cardiovasc Intervent Radiol. 33 (1), 2010, 41-52.
16) Golfieri, R. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 111 (2), 2014, 255-64.
17) Ikeda, M. et al. A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma : The JIVROSG-1302 PRESIDENT study. J Clin Oncol. 38 (15) suppl, 2020, 4518.
18) Bolondi, L. et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma : proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 32 (4), 2012, 348-59.
19) Kudo, M. et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma : TACTICS trial. Gut. 69 (8), 2020, 1492-501.
20) Kudo, M. et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond Up-To-Seven criteria and Child-Pugh A liver function : a proof-of-concept study. Cancers (Basel). 11 (8), 2019, 1084.
P.300 掲載の参考文献
1) Shiina, S. et al. Randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 129 (1), 2005, 122-30.
2) 杉浦信之ほか. 超音波映像下経皮的腫瘍内エタノール注入による小肝細胞癌の治療. 肝臓. 24 (8), 1983, 920.
3) Ishii, H. et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer. 77 (9), 1996, 1792-6.
4) Seki, T. et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 74 (3), 1994, 817-25.
5) Lencioni, RA. et al. Small hepatocellular carcinoma in cirrhosis : randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 22 (1), 2003, 235-40.
7) Seror, O. et al. Histopathological comparison of monopolar versus no-touch multipolar radiofrequency ablation to treat hepatocellular carcinoma within Milan criteria. J Vasc Interv Radiol. 25 (4), 2014, 599-607.
8) 清水遼ほか. 可変型電極を用いた肝癌に対するラジオ波焼灼術の経験. 肝臓. 57 (3), 2016, 135-7.
11) Lencioni, RA. et al. Early-stage hepatocellular carcinoma in patients with cirrhosis : long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 23 (3), 2005, 961-7.
12) 日本肝癌研究追跡調査委員会. 第22回全国原発性肝癌追跡調査報告 (2012~2013). 肝臓. 62 (5), 2021, 251-99.
P.305 掲載の参考文献
2) Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial. Lancet. 391 (10126), 2018, 1163-73.
3) Kudo, M. et al. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma : Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer. 9 (3), 2020, 1-16.
4) Kawamura, Y. et al. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer. 9 (3), 2020, 1-18.
5) Finn, RS. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 382 (20), 2020, 1894-905.
6) Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389 (10064), 2017, 56-66.
7) Zhu, AX. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20 (2), 2019, 282-96.
8) Abou-Alfa, GK. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 379 (1), 2018, 54-63.
9) Kawamura, Y. et al. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res. 40 (10), 2010, 1006-14.
10) Chang, WC. et al. Histological grade of hepatocellular carcinoma correlates with arterial enhancement on gadoxetic acid-enhanced and diffusion-weighted MR images. Abdominal imaging. 39 (6), 2014, 1202-12.
11) Tanaka, H. et al. New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol. 49 (4), 2014, 755-63.
12) Seo, S. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 13 (2 Pt 1), 2007, 427-33.
13) Hatano, E. et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 30 (9), 2006, 1736-41.
14) Iwamoto, T. et al. Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma. Dig Dis. 34 (6), 2016, 679-86.
15) Kobayashi, T. et al. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. Eur Radiol. 25 (11), 2015, 3272-81.
16) Tada, T. et al. Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. Eur Radiol. 24 (9), 2014, 2157-66.
17) Yamashita, T. et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma : an analysis of Japanese subset. J Gastroenterol. 55 (1), 2020, 113-22.
18) Kunimoto, H. et al. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma. Oncology. 98 (11), 2020, 779-86.
19) Takahashi, A. et al. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res. 39 (9), 2019, 5149-56.
20) Harimoto, N. et al. The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma. Oncology. 78 (5-6), 2010, 361-8.
21) Kudo, M. et al. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function : A Proof-Of-Concept Study. Cancers (Basel). 11 (8), 2019, 1084.
22) Kudo, M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden : Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer. 8 (5), 2019, 299-311.
23) Kawamura, Y. et al. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer. 9 (6), 2020, 1-15.
P.311 掲載の参考文献
1) World Health Organization. WHO Definition of Palliative Care. 2002. http://www.who.int/cancer/palliative/definition/en/ (2021年5月20日閲覧).
2) 大坂巌ほか. わが国におけるWHO緩和ケア定義の定訳-デルファイ法を用いた緩和ケア関連18団体による共同作成-. Palliat Care Res. 14 (2), 2019, 61-6.
3) Tsuneto, S. "Development of palliative medicine in Asia". Textbook of Palliative Medicine and Supportive Care. 2nd ed. Bruera, E. et al. ed. CRC Press. Florida, 2015, 71-6.
4) Jennifer, S. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 363 (8), 2010, 733-42.
5) Kaasa, S. et al. Integration of oncology and palliative care : a Lancet Oncology Commission. Lancet Oncol. 19 (11), 2018, e588-653.
6) World health organization. WHO guideline for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018. https://www.who.int/publications/i/item/who-guidelines-forthe-pharmacological-and-radiotherapeutic-managementof-cancer-pain-in-adults-and-adolescents (2021年5月20日閲覧)
7) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン : 2020年版. 東京, 金原出版, 2020.
8) Bosilkovska, M. et al. Analgesics in Patients with Hepatic Impairment Pharmacology and Clinical Implications. Drugs. 72 (12), 2012, 1645-69.
9) Kobayashi, T. Japan Interventional Radiology in Oncology Study Group (JIVROSG). Phase I/II clinical study of percutaneous vertebroplasty (PVP) as palliation for painful malignant vertebral compression fractures (PMVCF) : JIVROSG-0202. Ann Oncol. 20 (12), 2009, 1943-7.
10) Murakami, R. The value of embolization therapy in painful osseous metastasis from hepatocellular carcinomas ; comparative study with radiation therapy. Br J Radiol. 69 (827), 1996, 1042-4.
11) 中根英敏ほか. ラジオ波焼灼術にて治療した肝細胞癌肋骨転移の1例. 日本消化器病学会雑誌. 100 (suppl-1.2), 2003, 284.
12) Kashima, M. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. J Roentgenol. 194 (2), 2010, 536-41.
13) Maria, J. et al. Advance Directives and Outcomes of Surrogate Decision Making before Death. N Engl J Med. 362 (13), 2010, 1211-8.
14) 厚生労働省. 終末期医療の決定プロセスに関するガイドライン. 2007. https://www.mhlw.go.jp/shingi/2007/05/dl/s0521-11a.pdf (2021年5月20日閲覧)
15) 木澤義之編. アドバンス・ケア・プランニング (人生会議). 患者・家族と創る日本版アドバンス・ケア・プランニング~人生最終段階の幸せを支える. 第3版. 神戸大学. 2019. https://www.med.kobe-u.ac.jp/jinsei/acp_kobe-u/acp_kobe-u/acp01/index.html (2021年5月20日閲覧)

[12] 肝移植

P.322 掲載の参考文献
1) 日本肝移植学会. 肝移植症例登録報告. 移植. 54 (2-3), 2019, 81-96.
2) 日本移植学会. 臓器移植ファクトブック 2019. 2019.
3) 後藤邦仁ほか. 急性肝不全に対する肝移植医療の現状と課題. 日本消化器病学会雑誌. 117 (9), 2020, 772-8.
4) 厚生労働省「難治性の肝疾患調査研究班」劇症肝炎分科会ワーキンググループ. 劇症肝炎における新たな肝移植ガイドライン作成の試み. 日本腹部救急医学会雑誌. 29 (4), 2009, 617-22.
5) Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 334 (11), 1996, 693-9.
6) Shimamura, T. et al. Expanded living donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey : the 5-5-500 rule-a retrospective study. Transpl Int. 32 (4), 2019, 356-68.
7) 厚生労働省. 第5 回肝臓移植の基準等に関する作業班. 資料2 肝臓移植希望者 (レシピエント) 選択基準で定める優先順位の検討. 2016. https://www.mhlw.go.jp/stf/shingi2/0000137429.html (2021年5月20日閲覧)
8) 公益社団法人日本臓器移植ネットワーク. 肝臓移植希望者 (レシピエント) 選択基準. 2019. https://www.jotnw.or.jp/news/detail.php?id=1-172 (2021年5月20日閲覧)
9) Umeshita, K. et al. Operative morbidity of living liver donors in Japan. Lancet. 362 (9385), 2003, 687-90.
P.329 掲載の参考文献
1) 日本肝移植学会. 肝移植症例登録報告. 移植. 54 (2-3), 2019, 81-96.
2) Marubashi, S. et al. Risk factors for graft dysfunction after adult-to-adult living donor liver transplantation. Transplant Proc. 38 (5), 2006, 1407-10.
3) Kaido, T. et al. Impact of Sarcopenia on Survival in Patients Undetgoing Living Donor Liver Transplantation. Am J Transplant. 13 (6), 2013, 1549-56.
4) Geisssler, EK. et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma : A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. 100 (1), 2013, 116-25.
5) Akinlolu, O. et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 349 (10), 2003, 931-40.
6) Engels, EA. et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 306 (17), 2011, 1891-901.

[13] 急性肝炎の診断と治療

P.339 掲載の参考文献
1) 日本肝臓学会編. "急性肝炎 (A型肝炎, B型肝炎, C型肝炎, D型肝炎, E型肝炎)". 肝臓専門医テキスト. 改訂第2版. 東京, 南光堂, 2016, 196-205.
2) 鈴木壱知ほか. 急性肝炎の栄養療法. 肝胆膵. 63 (3), 2011, 431-7.
3) 山崎一美ほか. 急性A型肝炎-最近の動向. 肝胆膵. 71 (6), 2015, 977-82.
4) Tamada, Y. et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 61 (5), 2012, 765-83.
5) 中尾瑠美子ほか. B型急性肝炎とHBVキャリア急性増悪のCLIA法IgM-HBc抗体価による判別. 肝臓. 47 (6), 2006, 279-82.
6) Ito, K. et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 59 (1), 2014, 89-97.
7) 日本肝臓学会肝炎診療ガイドライン作成委員会編. B型肝炎治療ガイドライン. 3.4版. http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b (2021年5月20日閲覧)
8) Ghany, MG. et al. Hepatitis C Guidance 2019 Update : American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 71 (2), 2020, 686-721.
9) European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 69 (2), 2018, 461-511.
10) 佐田通夫. 全国調査に基づくC型急性肝炎の感染経路および治療に関する研究. 厚生労働科学研究費補助金肝炎等克服緊急対策研究事業 (肝炎分野). C型肝炎ウイルスの感染者に対する治療の標準化に関する臨床研究. 2002年度総括・分担研究報告書 (主任研究者 熊田博光). 2003, 24-7.
11) Mitamura, K. Epidemiology of HDV infection in Japan. Prog Clin Biol Res. 364, 1991, 81-7.
12) 鈴木哲朗ほか. D型肝炎 疫学と病態. 臨床とウイルス. 48 (2), 2020, 150-3.
13) 高橋雅春ほか. D型肝炎の診断法の確立と分子疫学的研究の成果. 臨床とウイルス. 37 (4), 2009, 329-36.
14) 阿部敏紀ほか. 本邦に於けるE型肝炎ウイルス感染の統計学的・疫学的・ウイルス学的特徴 : 全国集計254例に基づく解析. 肝臓. 47 (8), 2006, 384-91.
P.350 掲載の参考文献
1) 厚生労働省「難治性の肝疾患に関する研究」班. 劇症肝炎の診断基準. 2003.
2) Gimson, AE. et al. Late onset hepatic failure : Clinical, serological and histological features. Hepatology. 6 (2), 1986, 288-94.
3) Polson, J. et al. AASLD Position Paper : The management of acute liver failure. Hepatology. 41 (5), 2005, 1179-97.
4) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班. 急性肝不全の診断基準. 2015年改訂版. 2015.
5) 厚生労働省「難治性の肝疾患に関する研究」班. 劇症肝炎の成因分類. 2003.
6) Oketani, M. et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 43 (2), 2013, 97-105.
7) Nakao, M. et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol. 53 (6), 2018, 752-69.
8) 厚生労働省「難治性の肝・胆道疾患に関する研究」班. 急性肝不全の成因分類. 2015年改訂版. 2015.
9) Takikawa, Y. et al. Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci. 51 (2), 2006, 359-64.
10) 武藤泰敏ほか. 平成4年 劇症肝炎全国集計. 厚生省特定疾患難治性の肝炎調査研究班. 平成5年度研究報告. 1994, 44-50.
11) Yoshiba, M. et al. Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis : multicenter study. J Gastroenterol. 37 (11), 2002, 916-21.
12) Takikawa, Y. et al. Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol. 51 (6), 2009, 1021-9.
13) 木曽真一ほか. "劇症肝炎". 消化器疾患治療マニュアル 改訂2版. 林紀夫・竹原徹郎監修. 京都, 金芳堂, 2013, 11-24.
14) 持田智ほか. 我が国における劇症肝炎, LOHFの実態. 日本消化器病学会雑誌. 99 (8), 2002, 895-904.
15) Tsubouchi, H. et al. Prediction of outcome in fulminant hepatic failure by serum human hepatocyte growth factor. Lancet. 340 (8814), 1992, 307.
17) Abe, M. et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res. 21 (3), 2001. 213-9.
18) 滝川一ほか. DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓. 46, 2005, 85-90.
19) 厚生労働省「難治性の肝疾患調査研究班」劇症肝炎分科会ワーキンググループ. 劇症肝炎における新たな肝移植ガイドライン作成の試み. 日本腹部救急医学会雑誌. 29 (4), 2009, 617-22.
20) 日本肝臓学会肝炎診療ガイドライン作成委員会編. B型肝炎治療ガイドライン. 3.4版. 2021. http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b (2021年5月20日閲覧)
21) Rolando, N. et al. Prospective study of bacterial infection in acute liver failure : an analysis of fifty patients. Hepatology. 11 (1), 1990, 49-53.
22) Rolando, N. et al. Fungal infection : a common, unrecognized complication of acute liver failure. J. Hepatol. 12 (1), 1991, 1-9.
23) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班編. "劇症肝炎の治療". 劇症肝炎の診療ガイド. 東京, 文光堂, 2010, 22-33.
24) 日本移植学会. 生体腎移植ガイドライン. 日本移植学会ホームページ. http://www.asas.or.jp/jst/pro/guideline/liver.php (2021年5月20日閲覧)
25) Yokoi, T. et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. TranfusApher Sci. 40 (1), 2009, 61-70.
26) Inoue, K. et al. Artificial liver support system using larger buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplant Proc. 41 (9), 2009, 259-61.
27) 江口晋ら. 肝移植症例登録報告. 移植. 54 (2-3), 2019, 81-96.

[14] 肝病理組織の基礎知識

P.354 掲載の参考文献
1) Lefkowitch, JH. Special stains in diagnostic liver pathology. Semin Diagn Pathol. 23 (3-4), 2006, 190-8.
2) Ikura, Y. et al. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol. 91 (7), 1996, 1367-73.
P.359 掲載の参考文献
1) Tarantino, G. et al. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol. Hepatol. 21 (8), 2006, 1266-8.
2) Szanto, P. et al. Steatosis in hepatitis C virus infection. Response to anti-viral therapy. J Gastrointestin Liver Dis. 15 (2), 2006, 117-24.
3) Desmet, VJ. et al. Classification of chronic hepatitis : diagnosis, grading and staging. Hepatology. 19 (6), 1994, 1513-20.
4) Lefkowitch, JH. et al. Pathological diagnosis of chronic hepatitis C : a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology. 104 (2), 1993, 595-603.
P.363 掲載の参考文献
2) Scheuer, PJ. Primary biliary cirrhosis. Proc R Soc Med. 60 (12), 1967, 1257-60.
3) Nakanuma Y, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens : Interobserver agreement. Pathol Int. 60 (3), 2010, 167-74.
P.366 掲載の参考文献
1) Kleiner, DE. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41 (6), 2005, 1313-21.
2) Younossi, ZM. et al. Pathologic criteria for nonalcoholic steatohepatitis : Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 53 (6), 2011, 1874-82.
P.369 掲載の参考文献
1) 神代正道. 小さい肝癌 : 病理形態学的立場から. 取扱い規約に沿った腫瘍鑑別診断アトラス : 肝臓. 奥平雅彦ほか編. 東京, 文光堂, 1991, 44-51.
3) Park, SY. et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 131 (10), 2007, 1561-7.
4) Chu, PG. et al. Keratin expression in human tissues and neoplasms. Histopathology. 40 (5), 2002, 403-39.
5) Borzio, M. et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis : a prospective study. Gastroenterology. 108 (3), 1995, 812-7.
6) Ganne-Carrie, N. et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology. 23 (5), 1996, 1112-8.

最近チェックした商品履歴

Loading...